Logo wahanariau.com
  2. New jersey

New jersey

Index
Globenewswire

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Sabtu, 11 Oktober 2025 - 02:25:54 Wib
Globenewswire

Verisk Names Saurabh Khemka President of Underwriting Solutions

Selasa, 30 September 2025 - 20:00:00 Wib
Globenewswire

Patients Taking AUSTEDO XR® (deutetrabenazine) Extended-release Tablets Reported Symptom Improvement and High Satisfaction

Senin, 22 September 2025 - 02:25:11 Wib
Globenewswire

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Senin, 22 September 2025 - 02:24:05 Wib
Globenewswire

AvePoint Announces Dual Listing on the Singapore Exchange to Continue Global Expansion

Sabtu, 20 September 2025 - 01:09:47 Wib
Globenewswire

AvePoint Announces Pricing of Public Offering

Selasa, 16 September 2025 - 20:00:00 Wib
Globenewswire

Kyowa Kirin Announces Late-Breaking Abstract Presentation at the European Academy of Dermatology and Venerology Congress

Kamis, 11 September 2025 - 19:30:00 Wib
Berita

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Rabu, 10 September 2025 - 04:08:15 Wib
Globenewswire

$152 Billion and Rising: New Report Shows Insurance Industry Facing Growing Average Annual Losses from Natural Catastrophes

Selasa, 02 September 2025 - 23:07:59 Wib
Globenewswire

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

Kamis, 28 Agustus 2025 - 22:10:36 Wib
Globenewswire

Boehringer Ingelheim and Palatin Technologies to Develop Potential First-in-class Melanocortin Receptor Targeted Treatment for Patients with Retinal Diseases

Selasa, 19 Agustus 2025 - 20:07:57 Wib
Globenewswire

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

Kamis, 07 Agustus 2025 - 00:14:16 Wib
Globenewswire

Verisk Signs Definitive Agreement to Acquire AccuLynx

Rabu, 30 Juli 2025 - 21:02:39 Wib
Globenewswire

Impulse Dynamics® Completes Enrollment of Pivotal Trial for CCM-D® HF System and Earns Category 1 CPT Codes for CCM® Therapy

Selasa, 29 Juli 2025 - 03:36:32 Wib
Globenewswire

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

Selasa, 08 Juli 2025 - 21:59:29 Wib
Globenewswire

Synchronoss Meraih Sertifikasi Kerangka Privasi Data UE-A.S.

Jumat, 27 Juni 2025 - 03:24:53 Wib
Globenewswire

Synchronoss Achieves EU-U.S. Data Privacy Framework Certification

Kamis, 26 Juni 2025 - 01:20:59 Wib
Globenewswire

KLOG Transport Solutions Delivers Cargo Visibility Across Europe Powered by ORBCOMM® Satellite IoT Technology

Rabu, 25 Juni 2025 - 02:01:41 Wib
Globenewswire

Spring Bio Solution Meluncurkan NCE Grid untuk Mendekode Peluang Pengajuan Para IV dan First-to-File

Kamis, 12 Juni 2025 - 18:30:00 Wib
Globenewswire

Spring Bio Solution Launches NCE Grid to decode Para IV Filing and First-to-File Opportunities

Rabu, 11 Juni 2025 - 17:00:00 Wib
Globenewswire

ORBCOMM® Launches CrewView to Enable Smart Containers to Fill the Last Gap in End-to-end Visibility While at Sea

Selasa, 03 Juni 2025 - 19:30:00 Wib
Globenewswire

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

Senin, 02 Juni 2025 - 03:23:09 Wib
Globenewswire

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with T

Senin, 02 Juni 2025 - 03:21:53 Wib
Globenewswire

Verisk Welcomes Christopher Perry and Sabra Purtill to its Board of Directors

Kamis, 22 Mei 2025 - 04:00:33 Wib
Globenewswire

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

Senin, 05 Mei 2025 - 21:43:51 Wib